Tethis, a Milan, Italy-based cancer diagnostics company, raised €15M in Funding.
The round was led by Enea TECH and Biomedical Foundation.
The company intends to use the funds to accelerate the development, validation and preparation for commercialization of its diagnostic platform.
Led by CEO Holger Neecke, Tethis is developing solutions for liquid biopsy, a non-invasive blood test that can detect traces of tumor circulating in the blood. The core of its research lies in its integrated analytical process that includes the See.d®blood sample preparation instrument, SmartBioSurface®slides treated with biocompatible nanomaterials, and artificial intelligence algorithms for identifying cellular elements of tumor origin.
This new funding round followed previous investments from Genextra and Indaco Venture Partners.
FinSMEs
14/01/2025